13F Pro13F Pro

BRAIDWELL LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1920938
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare89.3%$2.4B
  • Technology7.4%$199.0M
  • Other2.8%$75.7M
  • Financials0.5%$14.2M

AUM History

13fpro.ai/research/fund/braidwell-lp-1920938

Conviction and streaks

Concentrating · top 10 = 31.6%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

CAI$CAIConviction hold5.4% weight · held 5 quartersHNGE$HNGEConviction hold4.1% weight · held 4 quartersGKOS$GKOSConviction hold3.1% weight · held 10 quartersEWTX$EWTXConviction hold3.0% weight · held 8 quartersSYRE$SYREConviction hold2.9% weight · held 10 quartersCAI$CAIAccumulating+13% shares · 3 quarters runningIRTC$IRTCAccumulating+201% shares · 2 quarters runningATEC$ATECAccumulating+331% shares · 2 quarters runningTMDX$TMDXAccumulating+93% shares · 2 quarters runningDHR$DHRAccumulating+27% shares · 2 quarters runningKNSA$KNSATrimming-95% shares · 6 quarters runningNBIX$NBIXTrimming-72% shares · 5 quarters runningGH$GHTrimming-96% shares · 5 quarters runningKRYS$KRYSTrimming-82% shares · 4 quarters runningSYRE$SYRETrimming-66% shares · 3 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/braidwell-lp-1920938

BRAIDWELL LP 13F holdings — Q2 2026

$2.7B portfolio (-9.8% QoQ) · 86 holdings · Q2 2026 13F · top 10 are 32% of the stock portfolio

All holdings — BRAIDWELL LP (Q2 2026)

86 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
GLUE$GLUEMonte Rosa Therapeutics, Inc.$59.3M-24%
DNTH$DNTHDianthus Therapeutics, Inc. /DE/$58.0M-34%
NBIX$NBIXNEUROCRINE BIOSCIENCES INC$56.7M-48%
ATEC$ATECAlphatec Holdings, Inc.$56.5M+201%
GENB$GENBGenerate Biomedicines, Inc.$55.4M-9%
MRVI$MRVIMARAVAI LIFESCIENCES HOLDINGS, INC.$54.3M-15%
KRYS$KRYSKrystal Biotech, Inc.$47.9M-29%
HUM$HUMHUMANA INC$45.5MNew
TMO$TMOTHERMO FISHER SCIENTIFIC INC.$44.8M-4%
KYMR$KYMRKymera Therapeutics, Inc.$43.4M+12%
RYTM$RYTMRHYTHM PHARMACEUTICALS, INC.$42.3M+23%
DMRA$DMRADamora Therapeutics, Inc.$42.1M+81%
ACAD$ACADACADIA PHARMACEUTICALS INC$41.7M-33%
BTSG$BTSGBrightSpring Health Services, Inc.$41.6M-41%
TMDX$TMDXTransMedics Group, Inc.$40.5M+85%

What changed in Q2 2026

Against the previous quarter's 13F: 24 new, 21 added to, 36 trimmed, 25 sold out. Share-count changes; largest moves by dollar size first.

New positions (24)

  • HUM$HUMHUMANA INC$45.5M

    first bought this quarter

  • MAZE$MAZEMaze Therapeutics, Inc.$34.0M

    first bought this quarter

  • AVTX$AVTXAvalo Therapeutics, Inc.$30.1M

    first bought this quarter

  • ALMR$ALMRAlamar Biosciences, Inc.$29.4M

    first bought this quarter

  • ORKA$ORKAOruka Therapeutics, Inc.$26.5M

    first bought this quarter

  • AVLN$AVLNAvalyn Pharma Inc.$26.4M

    first bought this quarter

+18 more in the Excel export

Added to (21)

  • ATEC$ATECAlphatec Holdings, Inc.+201%

    now $56.5M · held 2 qtrs, 2 adds in a row

  • DMRA$DMRADamora Therapeutics, Inc.+81%

    now $42.1M · held 2 qtrs, 2 adds in a row

  • TMDX$TMDXTransMedics Group, Inc.+85%

    now $40.5M · held 7 qtrs, 2 adds in a row

  • RGEN$RGENREPLIGEN CORP+273%

    now $24.2M · held 10+ qtrs

  • NKTR$NKTRNEKTAR THERAPEUTICS+113%

    now $33.1M · held 2 qtrs, 2 adds in a row

  • CLYM$CLYMClimb Bio, Inc.+83%

    now $36.5M · held 2 qtrs, 2 adds in a row

+15 more in the Excel export

Trimmed (36)

  • ARGX$ARGXARGENX SE-79%

    now $16.4M · held 10+ qtrs

  • NBIX$NBIXNEUROCRINE BIOSCIENCES INC-48%

    now $56.7M · held 10+ qtrs, 5 trims in a row

  • GH$GHGuardant Health, Inc.-70%

    now $22.2M · held 10+ qtrs, 3 trims in a row

  • MBX$MBXMBX Biosciences, Inc.-52%

    now $39.2M · held 3 qtrs

  • CLDX$CLDXCelldex Therapeutics, Inc.-68%

    now $16.2M · held 4 qtrs, 2 trims in a row

  • DNTH$DNTHDianthus Therapeutics, Inc. /DE/-34%

    now $58.0M · held 4 qtrs, 2 trims in a row

+30 more in the Excel export

Sold out (25)

  • CNTA$CNTACentessa Pharmaceuticals plcwas $78.9M

    held 2 qtrs

  • NUVL$NUVLNuvalent, Inc.was $71.8M

    held 6 qtrs

  • CGON$CGONCG Oncology, Inc.was $66.7M

    held 9+ qtrs

  • APGE$APGEApogee Therapeutics, Inc.was $40.3M

    held 9+ qtrs

  • PEN$PENPenumbra Incwas $34.6M
  • SLNO$SLNOSOLENO THERAPEUTICS INCwas $32.1M

+19 more in the Excel export

Firm AUM (Form ADV): $3.6B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F BRAIDWELL LP has filed, 14 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow BRAIDWELL?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of BRAIDWELL's top 20 holdings: 50/100 (our AI quality score, weighted by position size; 16 of the 20 are scored)

Top 10 since filing

+4.3%

Value-weighted move of the 10 largest stock positions

Turnover

19%

Last quarter; 81% over the last 4

Top 10 weight

32%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

57%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

BRAIDWELL LP disclosed 86 positions worth $2.7B in its Form 13F-HR for Q2 2026, led by $CAI (Caris Life Sciences, Inc.) at 5.4% of the equity portfolio, followed by $HNGE and $GKOS. During the quarter the fund opened 24 new positions and exited 25 — including a new stake in $HUM and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (89.3% of disclosed assets). All figures are sourced directly from BRAIDWELL LP’s Form 13F-HR filing with the SEC under CIK 1920938.

Funds like this

managers whose biggest positions overlap BRAIDWELL's
RTW INVESTMENTS, LP$11.71B 13F book · 6 shared top holdingsSYREIRTCNBIXACADBAKER BROS. ADVISORS LP$19.96B 13F book · 8 shared top holdingsKODKYMRRYTMACADPERCEPTIVE ADVISORS LLC$6.66B 13F book · 7 shared top holdingsSYREEWTXRYTMNRIXORBIMED ADVISORS LLC$5.40B 13F book · 8 shared top holdingsEWTXMBXHUMCRVSCormorant Asset Management, LP$1.95B 13F book · 8 shared top holdingsEWTXDNTHMBXCLYMTCG Crossover Management, LLC$4.16B 13F book · 6 shared top holdingsSYREGLUEDNTHKOD

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: BRAIDWELL LP

13F Pro is an AI hedge fund tracker and stock research platform. For BRAIDWELL LP (SEC CIK: 1920938), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in BRAIDWELL LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.